Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The cost-effectiveness of paliperidone extended release in Spain.

Treur M, Baca E, Bobes J, Cañas F, Salvador L, Gonzalez B, Heeg B.

J Med Econ. 2012;15 Suppl 1:26-34. doi: 10.3111/13696998.2012.734884. Epub 2012 Oct 23.

PMID:
23016569
2.

Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

Zeidler J, Mahlich J, Greiner W, Heres S.

Appl Health Econ Health Policy. 2013 Oct;11(5):509-21. doi: 10.1007/s40258-013-0050-0. Erratum in: Appl Health Econ Health Policy. 2013 Dec;11(6):689.

PMID:
23975630
3.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
4.

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.

Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.

Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x.

5.

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.

Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD.

J Med Econ. 2012;15(3):531-47. doi: 10.3111/13696998.2012.662923. Epub 2012 Feb 21.

PMID:
22304338
6.

The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving.

Edwards NC, Muser E, Doshi D, Fastenau J.

J Med Econ. 2012;15(4):623-34. doi: 10.3111/13696998.2012.667465. Epub 2012 Feb 29.

PMID:
22332706
7.

Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.

Jones MP, Nicholl D, Trakas K.

Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99.

PMID:
20497747
8.

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

Fowler JA, Bettinger TL, Argo TR.

Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011. Review.

PMID:
18343262
9.
10.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
11.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
12.

Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.

Citrome L, Kamat SA, Sapin C, Baker RA, Eramo A, Ortendahl J, Gutierrez B, Hansen K, Bentley TG.

J Med Econ. 2014 Aug;17(8):567-76. doi: 10.3111/13696998.2014.917089. Epub 2014 May 12.

PMID:
24758296
13.

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A.

Biol Psychiatry. 2007 Dec 15;62(12):1363-70. Epub 2007 Jun 28.

PMID:
17601495
14.

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.

Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.

Am J Geriatr Psychiatry. 2008 Jan;16(1):31-43. doi: 10.1097/JGP.0b013e31815a3e7a.

PMID:
18165460
15.

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses.

García-Ruiz AJ, Pérez-Costillas L, Montesinos AC, Alcalde J, Oyagüez I, Casado MA.

Health Econ Rev. 2012 Apr 10;2(1):8. doi: 10.1186/2191-1991-2-8.

16.

Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.

Knapp M, Locklear J, Järbrink K.

Curr Med Res Opin. 2009 Jul;25(7):1593-603. doi: 10.1185/03007990903010623.

PMID:
19469696
17.

Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.

Tempest M, Sapin C, Beillat M, Robinson P, Treur M.

J Ment Health Policy Econ. 2015 Dec;18(4):185-200.

PMID:
26729007
18.
19.

Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.

Rodríguez-Martínez A, Quilo CG.

Clin Drug Investig. 2013 Dec;33(12):867-76. doi: 10.1007/s40261-013-0100-2. Review.

PMID:
24241935
20.

Supplemental Content

Support Center